Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the ...
Merck and EyeBio announce the initiation of the Phase 2b/3 BRUNELLO trial evaluating Restoret (MK-3000) for diabetic macular edema (DME). MK-3000 is an investigational tetravalent, tri-specific antibody acting as an agonist of the Wnt signaling pathway. The trial follows positive results from the Phase 1/2 AMARONE study.
Related Clinical Trials
Reference News
MSD and EyeBio initiate Phase IIb/III BRUNELLO trial of Restoret (MK-3000) for diabetic macular oedema, comparing two doses with ranibizumab. The trial features a personalised treatment interval algorithm and evaluates safety and visual acuity change as primary endpoints, building on Phase I/II AMARONE study results.
Merck and EyeBio initiate Phase 2b/3 BRUNELLO trial for Restoret™ (MK-3000) to treat diabetic macular edema (DME), based on positive Phase 1/2 AMARONE study results. MK-3000 is a first-in-class tetravalent, tri-specific Wnt agonist antibody aiming to reduce vascular leakage in retinal diseases.
Merck and EyeBio announce the initiation of the Phase 2b/3 BRUNELLO trial evaluating Restoret (MK-3000) for diabetic macular edema (DME). MK-3000 is an investigational tetravalent, tri-specific antibody acting as an agonist of the Wnt signaling pathway. The trial follows positive results from the Phase 1/2 AMARONE study.
Merck and EyeBio initiate Phase 2b/3 BRUNELLO trial for MK-3000, a first-in-class tetravalent, tri-specific antibody for diabetic macular edema (DME).
Merck and EyeBio initiate Phase 2b/3 BRUNELLO trial evaluating Restoret (MK-3000) for diabetic macular edema (DME), based on Phase 1/2 AMARONE study results.